Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

ClinicalTrials.gov ID: NCT00224055

Public ClinicalTrials.gov record NCT00224055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).

Study identification

NCT ID: NCT00224055
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Watson Pharmaceuticals; Industry
Enrollment: 89 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2003 (Type not available)
Primary completion: Sep 2004 (Actual)
Completion: Sep 2004 (Actual)
Last update posted: Mar 29, 2012

2003 – 2004

United States locations

U.S. sites: 23
U.S. states: 17
U.S. cities: 23

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	—	—
Not listed	Los Angeles	California	—	—
Not listed	Palo Alto	California	—	—
Not listed	San Diego	California	—	—
Not listed	Hines	Illinois	—	—
Not listed	Indianapolis	Indiana	—	—
Not listed	Shreveport	Louisiana	—	—
Not listed	Baltimore	Maryland	—	—
Not listed	Springfield	Massachusetts	—	—
Not listed	Detroit	Michigan	—	—
Not listed	St Louis	Missouri	—	—
Not listed	Birmingham	New York	—	—
Not listed	Mineola	New York	—	—
Not listed	New York	New York	—	—
Not listed	The Bronx	New York	—	—
Not listed	Chapel Hill	North Carolina	—	—
Not listed	Cleveland	Ohio	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Charlotte	South Carolina	—	—
Not listed	Chattanooga	Tennessee	—	—
Not listed	Memphis	Tennessee	—	—
Not listed	Houston	Texas	—	—
Not listed	Fairfax	Virginia	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00224055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 29, 2012 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00224055 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →